Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 34Cyclophosphamide 34Peripheral Blood Stem Cell Transplantation 23Busulfan 22Mycophenolic Acid 21Cyclosporine 20Whole-Body Irradiation 19Tacrolimus 18Antilymphocyte Serum 18Melphalan 16Filgrastim 16Radiotherapy 15Methotrexate 14fludarabine 12Cord Blood Stem Cell Transplantation 12Methylprednisolone 10Cytarabine 10Etoposide 8sargramostim 6Granulocyte Colony-Stimulating Factor 5Cyclosporins 5Alemtuzumab 4thymoglobulin 3merphos 3Tretinoin 3Thiotepa 3Thalidomide 3Sirolimus 3Rituximab 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × monalizumab × Classical hematology × Clear all
NCT06892223 2025-03-24

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Istituto Clinico Humanitas

Phase 2 Recruiting
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡